09Oct 2023
Safety of Prolonged Use of Mineralocorticoid Receptor Antagonists in Heart Failure Patients with Reduced Ejection Fraction and Advanced Kidney Disease

Safety of Prolonged Use of Mineralocorticoid Receptor Antagonists in Heart Failure Patients with Reduced Ejection Fraction and Advanced Kidney Disease

A study conducted on a real-world population of heart failure patients with reduced ejection fraction (HFrEF) investigated the safety of using mineralocorticoid receptor antagonists (MRAs) across a range of estimated glomerular filtration rates (eGFR), including severe chronic kidney disease (CKD). Of the 33,942 patients analyzed, 51% received MRAs with varying eGFR levels. The study found that MRA use was not associated with a higher risk of renal events, all-cause mortality, or hospitalization, regardless of eGFR. This research suggests that MRAs may be safe for HFrEF patients with CKD, addressing concerns about renal safety.

  • #cardiology

Like

Save

Share